Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Vanguard Group Inc.

Key Points

• Vanguard Group trimmed its position in Arrowhead by 4.6% in Q4, selling 742,749 shares and now holds 15,293,121 shares (about 11.25% of the company) valued at roughly $1.015 billion.
• Arrowhead's latest quarter showed an EPS miss ($0.22 vs. $0.60 expected) but a revenue beat ($264.03M vs. $225.66M), with revenue up an extraordinary ~10,461% year‑over‑year and a market capitalization around $10.48 billion.
• Analyst sentiment is positive (consensus “Moderate Buy” with an average target of $84.20 and multiple firms raising targets), while insiders sold about 33,095 shares (~$2.33M) recently under Rule 10b5‑1 plans.

Vanguard Group Inc. lowered its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 4.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,293,121 shares of the biotechnology company's stock after selling 742,749 shares during the period. Vanguard Group Inc. owned 11.25% of Arrowhead Pharmaceuticals worth $1,015,310,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in ARWR. Royal Bank of Canada lifted its stake in Arrowhead Pharmaceuticals by 30.2% during the first quarter. Royal Bank of Canada now owns 45,239 shares of the biotechnology company's stock worth $576,000 after purchasing an additional 10,496 shares during the last quarter. AQR Capital Management LLC purchased a new stake in Arrowhead Pharmaceuticals during the first quarter worth approximately $514,000. Goldman Sachs Group Inc. lifted its stake in Arrowhead Pharmaceuticals by 34.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company's stock worth $22,189,000 after purchasing an additional 447,456 shares during the last quarter. Empowered Funds LLC lifted its stake in Arrowhead Pharmaceuticals by 6.9% during the first quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company's stock worth $194,000 after purchasing an additional 979 shares during the last quarter. Finally, Focus Partners Wealth lifted its stake in Arrowhead Pharmaceuticals by 1,339.5% during the first quarter. Focus Partners Wealth now owns 16,252 shares of the biotechnology company's stock worth $207,000 after purchasing an additional 15,123 shares during the last quarter. Hedge funds and other institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Stock Up 1.8%

ARWR opened at $74.81 on Friday. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.38 and a quick ratio of 3.38. The business has a 50 day simple moving average of $63.47 and a 200-day simple moving average of $59.20. The stock has a market capitalization of $10.48 billion, a P/E ratio of 48.90 and a beta of 1.28. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $12.44 and a 12 month high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings results on Thursday, February 5th. The biotechnology company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.60 by ($0.38). The business had revenue of $264.03 million during the quarter, compared to analyst estimates of $225.66 million. Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The firm's quarterly revenue was up 10461.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.39) earnings per share. On average, equities analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.37 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Weiss Ratings raised Arrowhead Pharmaceuticals from a "sell (d-)" rating to a "hold (c-)" rating in a research report on Friday, February 6th. The Goldman Sachs Group lifted their price target on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a "neutral" rating in a research report on Wednesday, January 7th. Chardan Capital lifted their price target on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a "buy" rating in a research report on Wednesday, January 7th. B. Riley Financial lifted their price target on Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a "buy" rating in a research report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. assumed coverage on Arrowhead Pharmaceuticals in a research report on Friday. They set an "overweight" rating and a $88.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $84.20.

Insider Activity at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 10,000 shares of the firm's stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total value of $750,000.00. Following the completion of the sale, the insider directly owned 226,958 shares of the company's stock, valued at $17,021,850. This trade represents a 4.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of the firm's stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $71.35, for a total value of $934,328.25. Following the completion of the transaction, the chief financial officer directly owned 162,905 shares of the company's stock, valued at $11,623,271.75. The trade was a 7.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 33,095 shares of company stock valued at $2,326,228 over the last three months. Insiders own 3.60% of the company's stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.